营养不良,认知衰退和痴呆症:合作的PROMED-COG聚合队列研究研究
Marianna Noale1, Federica Prinelli2, Silvia Conti2
1Neuroscience Institute, Aging Branch, National Research Council (CNR), Viale Giuseppe Colombo 3, 35121 Padova, Italy.
Clinical nutrition (Edinburgh, Scotland)
|September 12, 2024
概括
营养不良在老年人中很常见,并且与认知能力下降和痴呆症的风险更高有关. 早期发现和预防营养不良可能有助于对抗神经退行.
科学领域:
- 老年学是一门学科.
- 神经科学是一个神经科学.
- 公共卫生 公共卫生
背景情况:
- 营养不良对认知功能的影响需要进一步巩固.
- 为了打击营养不良和促进健康的神经认知衰老 (PROMED-COG) 项目,研究了这种联系.
研究的目的:
- 评估营养不良和认知衰退之间的关联.
- 评估营养不良和老年痴呆症之间的关系.
主要方法:
- 来自意大利三个基于人口的研究 (ILSA,Pro.V.A.,BEST-FU) 的统一后期数据.
- 全球营养不良领导倡议 (GLIM) 标准用于定义营养不良.
- 考克斯比例危险回归模型分析了认知衰退 (MMSE) 和痴呆发病率.
主要成果:
- 9071个个体 (42-101岁) 的聚合队列; 营养不良的流行率为14.3%.
- 营养不良与认知能力下降 (HR 1.20) 和痴呆症发病率 (HR 1.57) 的增加有关.
- 营养不良和认知能力下降之间的关联在男性中更强.
结论:
- 营养不良在老年人中很普遍,增加了认知能力下降和痴呆症的风险.
- 预防和早期发现营养不良可能是对抗神经退行症的关键非药物战略.
相关概念视频
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
108
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
108
Dementia
107
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
107
Cognitive Development During Adulthood
68
Cognitive development continues throughout adulthood, undergoing significant shifts across early, middle, and late stages. Individual transition occurs from adolescent idealism to pragmatic and adaptable thinking in early adulthood. During this period, individuals learn to integrate personal beliefs with the recognition that other perspectives are equally valid. Exposure to the complexities of modern society, diverse experiences, and higher education contribute to this adaptive thought process,...
68
Alzheimer's Disease: Overview
452
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
452
Psychoneuroimmunology: Diabetes and Cancer
26
Chronic stress has been linked to both the onset and progression of serious health conditions, including Type 2 diabetes and cancer. Type 2 diabetes, a widespread chronic illness, is closely associated with obesity and insulin resistance, both of which often worsen under stress. Studies indicate that men experiencing high levels of chronic stress face a 45% higher risk of developing diabetes compared to those with minimal stress. Stress triggers physiological responses that elevate blood...
26
Alzheimer's Disease: Treatment
170
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
170


